Hemostemix Starts its Roll-up of Cardiology Practices, Acquiring its First Two

Rhea-AI Summary

Hemostemix (OTCQB: HMTXF) announced a binding Letter of Intent to acquire two cardiology practices from Dr. Roberto Fernandez-de-Castro and Dr. Hector Rosario Figueroa for 2,000,000 common shares each (subject to adjustment and TSXV approval).

The two cardiologists have combined experience treating more than 200 patients with ACP-01 across multiple cardiovascular indications, and will help implement ACP-01 therapy in the Dominican Republic and the Bahamas. Hemostemix says the acquisitions create anchor practices to accelerate commercialization and future trial expansion and to generate predictable patient flow.

The TSXV approved a financing extension to December 1, 2025. To date the company raised $461,230 via 4,193,000 Units at $0.11 per Unit; each Unit includes one share and one warrant exercisable at $0.15 for two years with an accelerated expiry clause.

Positive

• 4,000,000 shares proposed to be issued for two practices
• >200 ACP-01 patients treated by the two cardiologists combined
• Anchor practices planned for Dominican Republic and Bahamas
• $461,230 raised via non‑brokered private placement to date

Negative

• Acquisitions subject to TSXV approval
• Proposed issuance of 4,000,000 common shares may dilute shareholders
• Outstanding warrants exercisable at $0.15 could further dilute
• Financing extension limited to December 1, 2025 deadline

News Market Reaction – HMTXF

-3.23%

1 alert

-3.23% News Effect

On the day this news was published, HMTXF declined 3.23%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Practice acquisition shares: 2,000,000 shares each ACP-01 patient treatments: more than 200 patients Private placement price: $0.11 per Unit +5 more

8 metrics

Practice acquisition shares 2,000,000 shares each Share consideration for each cardiology practice under LOI

ACP-01 patient treatments more than 200 patients Combined ACP-01 treatment experience of two cardiologists

Private placement price $0.11 per Unit Non-brokered private placement Unit price

Gross proceeds raised $461,230 Proceeds from 4,193,000 Units issued to date

Units issued 4,193,000 Units Units sold in current private placement so far

Warrant exercise price $0.15 per share Exercise price for each warrant, valid for two years

Acceleration trigger price $0.185 per share 10-day weighted average price threshold for warrant acceleration

Warrant term 2 years Duration from closing date before warrant expiry (subject to acceleration)

Market Reality Check

Price: $0.0573 Vol: Volume 22,000 is 1.53x th...

high vol

$0.0573 Last Close

Volume Volume 22,000 is 1.53x the 20-day average of 14,402, indicating elevated interest pre-news. high

Technical Price 0.06364 is trading below the 200-day MA at 0.09, reflecting a longer-term downtrend.

Peers on Argus

HMTXF gained 0.95% while peers were mixed: MRES up 15.96%, RDTCF sharply higher ...

HMTXF gained 0.95% while peers were mixed: MRES up 15.96%, RDTCF sharply higher at 2400%, TELIF down 7.63%, and others flat. This points to stock-specific dynamics rather than a uniform biotech sector move.

Historical Context

5 past events · Latest: Dec 10 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 10	FDA meeting & financing	Positive	+0.9%	FDA Pre-IND meeting scheduled and proposed $960,000 private placement.
Dec 03	Conference presentation	Positive	-8.9%	Innovation conference highlighting ACP-01/VesCell wound-healing data.
Dec 02	Conference & financing	Positive	-3.2%	DFCon attendance plus $518,440 private placement closing with warrants.
Nov 26	Clinic acquisitions	Positive	-3.2%	LOI to buy two cardiology practices and TSXV-approved financing extension.
Nov 18	Clinical data showcase	Positive	+6.6%	Wound care conference featuring Phase II ACP-01 outcomes and market sizing.

Pattern Detected

Recent news has mostly been positive (clinical data, financings, acquisitions), yet 3 of the last 5 events saw negative 24h price reactions, suggesting a tendency for the stock to sell off or fade on good news.

Recent Company History

Over the last month, Hemostemix reported multiple ACP-01 clinical data presentations and corporate financings, alongside this LOI to acquire two cardiology practices for 2,000,000 shares each. The company raised $461,230 via 4,193,000 Units at $0.11, followed by an additional private placement of $518,440. Clinical communications highlighted strong limb preservation and wound-healing outcomes across hundreds of subjects. Price reactions have been mixed, with both sharp gains and declines, indicating investors have not consistently rewarded these positive developments.

Market Pulse Summary

This announcement details a binding LOI to acquire two cardiology practices for 2,000,000 shares eac...

Analysis

This announcement details a binding LOI to acquire two cardiology practices for 2,000,000 shares each and extends Hemostemix’s ACP-01 footprint in the Dominican Republic and the Bahamas. It also confirms TSXV approval of a private placement raising $461,230 via 4,193,000 Units at $0.11 with two-year warrants at $0.15. Investors may watch how quickly these clinics integrate ACP-01, the pace of additional roll-up deals, and future financing structures.

Key Terms

binding letter of intent, non brokered private placement, common share purchase warrant, warrant, +4 more

8 terms

binding letter of intent financial

"pleased to announce a binding Letter of Intent for the acquisition"

A binding letter of intent is a short written agreement in which parties formally commit to the main terms of a proposed transaction — such as price, timeline and key conditions — before the full contract is completed. It matters to investors because it raises the chance the deal will actually happen and can change a company’s value and risk profile, much like a signed down-payment that holds buyers and sellers to core promises while final paperwork is finished.

non brokered private placement financial

"terms of the non brokered private placement of Units at $0.11"

A non-brokered private placement is a direct sale of a company’s securities, such as shares or bonds, to a limited group of investors without using an outside broker or dealer. It matters to investors because it can raise capital quickly with lower fees and less public disclosure, but may dilute existing ownership and provide fewer market checks on price — like borrowing from close contacts instead of taking a loan through a public bank.

common share purchase warrant financial

"one common share purchase warrant (a "Warrant")"

A common share purchase warrant is a tradable contract that gives its holder the right, but not the obligation, to buy a company’s common stock at a specified price within a set period. Think of it like a coupon for future shares: if the stock rises above the coupon price it can boost returns for the holder, but when used it increases the number of outstanding shares and can reduce each existing shareholder’s ownership and affect the company’s cash position.

warrant financial

"Each full Warrant entitles the holder to acquire one additional"

A warrant is a time-limited financial contract that gives its holder the right to buy a company's shares at a set price before a specified date, like a coupon that lets you purchase stock at a fixed discount for a limited time. It matters to investors because warrants offer leveraged exposure to a stock’s upside and can dilute existing shareholders if exercised, so they affect potential gains and the company’s outstanding share count.

accelerated expiry provision financial

"for a period of two (2) years ... subject to the accelerated expiry provision"

An accelerated expiry provision is a clause in a financial contract (like a warrant, option, or convertible security) that causes the instrument to expire earlier than its original date when certain events occur, such as a missed payment, regulatory change, delisting, or a corporate transaction. It matters to investors because it shortens the time they have to exercise or benefit from the security, which can reduce its value and force quicker decisions—similar to milk spoiling faster when left in heat, changing how and when you can use it.

weighted average price financial

"greater than a weighted average price of $0.185 per Common Share"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

ischemic cardiomyopathy medical

"ischemia-related indications (vascular dementia, ischemic cardiomyopathy, PAD"

Ischemic cardiomyopathy is a condition in which the heart’s main pumping muscle becomes weak because it hasn’t received enough blood over time, usually due to blockages in the arteries that feed the heart. For investors, it matters because it drives demand for treatments, devices and long‑term care, and it influences healthcare costs and the revenue prospects of companies developing drugs, surgeries, implants or diagnostic tools for heart disease—think of the heart as a pump clogged by narrowed fuel lines.

peripheral arterial disease medical

"Peripheral Arterial Disease, Chronic Limb-Threatening Ischemia"

Peripheral arterial disease is a condition where fatty buildup and narrowing in the arteries reduce blood flow to the legs and feet, causing pain, slow wound healing, and higher risk of infection. Investors care because PAD drives demand for diagnostics, drugs, medical devices and procedures, influences healthcare costs and reimbursement decisions, and can affect sales, regulatory milestones and long-term revenue for companies in cardiovascular and wound-care markets.

AI-generated analysis. Not financial advice.

Calgary, Alberta--(Newsfile Corp. - November 26, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), is pleased to announce a binding Letter of Intent for the acquisition of the first two cardiology practices under the Company's clinic roll-up and commercialization strategy. The practices of Dr. Roberto Manuel Fernandez-de-Castro and Dr. Hector Rosario Figueroa, two of the Dominican Republic's most respected interventional cardiologists, will be acquired by Hemostemix for 2,000,000 shares each, subject to adjustment and TSXV approval.

This marks the first of many acquisitions, as Hemostemix's long-term strategy to acquire profitable, accretive medical practices within which is can add ACP-01 treatments. Capable of generating a sustainable, predictable commercial stream of patients for treatment with ACP-01, the Company's operations strategy will focus on patient treatment flow, while the Company's sales team focus on leveraging the practitioner to practitioner dialogue to increase the number of practitioners treating with ACP-01 (patient volumes).

Two cardiologists with more than 200 ACP-01 patient treatments

Combined, Dr. Fernandez-de-Castro and Dr. Rosario Figueroa have treated more than 200 patients with ACP-01, making them among the most experienced ACP-01 clinicians globally. Given their track record as pioneers in the safe treatment of end-stage no option CVD patients, Dr. Fernandez de Castro and Dr. Rosario Figueroa have the credibly to attest to the safety, feasibility, clinical relevancy and observed efficacy of ACP-01 to patients, referring physicians, hospital partners, and regulators.

Their experience spans multiple indications, including:

• Angina

• Ischemic and Dilated Cardiomyopathy

• Congestive Heart Failure

• Peripheral Arterial Disease

• Chronic Limb-Threatening Ischemia

• Vascular Dementia.

Their clinical expertise, long-standing patient bases, and reputations within the Dominican Republic's medical community position them as ideal anchor practices for Hemostemix's first international clinical and commercial footprint.

Under the terms of the LOI, Dr. Roberto Fernandez-de-Castro and Dr. Rosario Figueroa: 

• Will each contribute his medical expertise and experience in cardiovascular disease treatments of Angina, Ischemic and Dilated Cardiomyopathy, Congestive Heart Failure, Peripheral Arterial Disease, Chronic Limb Threatening Ischemia, and Vascular Dementia.

• Will actively participate in the clinical implementation of ACP-01 therapy within the Dominican Republic and the Bahamas.

• Will facilitate the necessary regulatory approvals and interactions with Dominican Republic health authorities.

• Will, each, sell his existing medical practice to HEM in exchange for the issuance of 2,000,000 common shares.

The integration of these practices will commence Hemostemix clinical infrastructure, accelerate ACP-01 commercialization, and provide the foundation for future clinical trial expansion. It provides a turnkey profit structure that enables hands-on care and follow-up with ACP-01 recipients, which is a significant contributor to improved health outcomes.

This model is designed to be replicated across additional markets-including Florida, Puerto Rico, and Canada under various pathways.

"This acquisition is a transformational milestone for Hemostemix," stated Thomas Smeenk, CEO. Dr. Fernandez-de-Castro and Dr. Rosario Figueroa are world-class cardiologists who have successfully treated 200 ACP-01 patients. Their firsthand experience, results as published, and clinical conviction provide a powerful foundation for accelerating ACP-01 in North America. These acquisitions are the first of many, as they enable us to focus advertising and patients flow in a regulatory compliant manner that is financially rewarding," Smeenk said.

TSXV Financing Extension
The TSXV has approved an extension to December 1st of the terms of the non brokered private placement of Units at $0.11 as announced on October 8, 2025, and as updated November 4, 2025. The Company raised aggregate gross proceeds of $461,230 through the issuance of 4,193,000 units ("Units") at a price of $0.11 per Unit, to-date. Each Unit consists of one common share in the capital of the Company (a "Common Share") and one common share purchase warrant (a "Warrant"). Each full Warrant entitles the holder to acquire one additional Common Share at a price of $0.15 per share for a period of two (2) years from the closing date of the Offering, subject to the accelerated expiry provision described as follows. If, on any 10 consecutive trading days occurring after four months and one day has elapsed following the closing date, the closing sales price of the Common Shares (or the closing bid, if no sales were reported on a trading day) as quoted on the TSX Venture Exchange (the "Exchange") is greater than a weighted average price of $0.185 per Common Share, the Company may provide notice in writing to the holders of the Warrants by issuance of a press release that the expiry date of the Warrants will be accelerated to the date that is 30 days following such press release.

ABOUT HEMOSTEMIX
Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapy, VesCell™ (ACP-01). Hemostemix has completed seven clinical studies of 318 subjects and published its results in eleven peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared to a five year mortality rate of 50% in the CLTI patient population, UBC and U of T reported to the 41st meeting of vascular surgeons: 0% mortality, cessation of pain, wound healing in 83% of patients followed for up to 4.5 years, as a midpoint result. For more information, please visit www.hemostemix.com.

For further information, please contact: Thomas Smeenk, President, CEO EM: tsmeenk@hemostemix.com / PH: 905-580-4170

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to the Phase I clinical trial of ACP-01 as a treatment for Vascular Dementia, and the treatment of pain related to CLTI in Florida and other jurisdictions related to angina, peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia with Angiogenic Cell Precursors (ACP-01) in furtherance of sales of VesCell™ (ACP-01), and the commercialization of ACP-01 via the sale of compassionate treatments under Florida SB 1768. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of any litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and, Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR+ website at www.sedarplus.ca. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/276108

FAQ

What did Hemostemix (HMTXF) announce on November 26, 2025?

A binding LOI to acquire two cardiology practices for 2,000,000 shares each, subject to TSXV approval.

How many ACP-01 patients have the acquired cardiologists treated for HMTXF?

Combined, they have treated more than 200 patients with ACP-01.

What financing update did Hemostemix (HMTXF) provide on November 26, 2025?

TSXV approved a financing extension to December 1, 2025; the company raised $461,230 via 4,193,000 Units at $0.11.

What are the warrant terms included in Hemostemix's private placement (HMTXF)?

Each Unit includes a warrant exercisable at $0.15 for two years with an accelerated expiry clause.

Where will Hemostemix implement ACP-01 following the acquisitions?

The company plans clinical implementation in the Dominican Republic and the Bahamas with an intent to replicate the model in other markets.